Cell Purity Assessment
Cell Purity Assessment - Related Videos
08:02
Determination of Immune Cell Identity and Purity Using Epigenetic-Based Quantitative PCR
0 Views •
Cited by 1 •
2020
Here we describe a robust method of determining immune cell identity and purity through epigenetic signatures detected using quantitative PCR (qPCR). DNA demethylation at a specific locus serves as a unique identifier for a particular cell type and allows for identification of CD8+, regulatory, or Th17 T cells.
12:17
Detection and Isolation of Apoptotic Bodies to High Purity
0 Views •
Cited by 29 •
2018
A workflow using flow cytometry or differential centrifugation is developed to detect, quantify and isolate apoptotic bodies from an apoptotic sample to high purity.
12:06
Synthesis of High Purity Nonsymmetric Dialkylphosphinic Acid Extractants
0 Views •
Cited by 6 •
2017
A protocol for the synthesis of high purity nonsymmetric dialkylphosphinic acid extractants is presented, taking (2,3-dimethylbutyl)(2,4,4'-trimethylpentyl)phosphinic acid as an example.
07:54
Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility
0 Views •
Cited by 22 •
2017
Here, we present a protocol to isolate microglia from postnatal mouse pups (day 1) for in vitro experimentation. This improvised method of isolation generates both high yield and purity, a significant advantage over alternate methods that allows broad range experimentation for the purposes of elucidating microglial biology.
09:49
Induction and Assessment of Class Switch Recombination in Purified Murine B Cells
0 Views •
Cited by 7 •
2010
Following antigen exposure, subpopulations of activated B cells undergo a process known as class switch recombination (CSR) to produce antibody isotypes with distinct effector functions. The protocol outlined in this report explains how CSR can be induced and analyzed in vitro for the purposes of studying B cell function.
FAQs
Morphological examination provides visual information about whether cells appear consistent with the intended preparation, whereas marker-based methods identify target cells through characteristic cellular markers. Using both approaches can strengthen interpretation because appearance alone may not distinguish closely related cell types, while markers provide composition-focused evidence. Their combined use supports more reliable evaluation of cell preparations in medical research and therapeutic development.
Purity measurements are more informative when considered alongside viability and contamination results. Viability indicates whether the preparation contains living cells suitable for the intended use, while contamination testing identifies unwanted quality problems that cellular composition alone may not reveal. Together, these assessments help distinguish a preparation that contains the desired cell type from one that is also sufficiently intact and suitable for further work.
Standardized assessment creates a consistent basis for evaluating preparations across experiments, disease models, and manufacturing stages. Without comparable procedures, differences in isolation, culture, or measurement can make results difficult to interpret. Consistency improves reproducibility, supports quality control, and helps researchers determine whether observed clinical or experimental outcomes reflect biological effects rather than variation in sample evaluation.
A workflow can begin with morphological examination of the preparation, followed by marker-based analysis such as immunostaining or flow cytometry to identify intended and unwanted cell types. Viability and contamination tests then add information about overall sample quality. Reviewing these findings together allows the preparation to be evaluated against its intended cellular composition and supports decisions about subsequent research or manufacturing use.
The assessment is particularly important when cellular composition can affect the reliability or safety of an outcome. Medical researchers use it when developing disease models and interpreting experiments, while diagnostics may depend on accurate characterization of cell preparations. In cell-based therapy development, purity measurements contribute to monitoring product quality and provide evidence that manufacturing processes remain consistent.
Purity measurements can be used at relevant stages of cell isolation, culture, and manufacturing to identify changes in cellular composition or sample quality. Comparing results over these stages helps reveal whether unwanted cell types emerge or whether preparation quality declines. This monitoring supports process control, improves consistency between preparations, and strengthens interpretation of research and clinical outcomes.